Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

• Results Overview

  Dupilumab treatment showed rapid and significant improvement in eczema symptoms compared to placebo, with most patients showing at least 50% improvement in their condition. The medication was well-tolerated with mainly mild side effects like nasopharyngitis and headache.

• Study Summary

  Num Participants:

  None

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'EASI-50': 85, 'IGA 0-1': 40, 'Pruritus': 55.7}

  Efficacy End Points Control:

  {'EASI-50': 35, 'IGA 0-1': 7, 'Pruritus': 15.1}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nasopharyngitis	Low
  Headache	Low

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Skin Infection	Medium